Targeting Cell Signalling Pathways: A Short Review on Tyrosine Kinase Inhibitors
International Journal of Advanced Research in Science Communication and Technology · 22.07.2026 · 17
DOI: 10.48175/ijarsct-37803 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Advanced Research in Science Communication and Technology, online erschienen am 22.07.2026. Verfasst von Tasleem und 2 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
This short review discusses about tyrosine kinase inhibitors (TyKI) as a potential targeting cell signalling pathway blocker playing active role as anticancer drugs. We learn about various TyKI drugs developed for oncological conditions are BCR-ABL (B cell Receptor fusion Abelson) Inhibitors, EGFR(Epidermal Growth Factor Receptor) Inhibitors, VEGFR (Vascular Epidermal Growth Factor Receptor) Inhibitor and BTK (Bruton’s Tyrosine Kinase) Inhibitors used successfully in chemotherapy. Like any anticancer drug class TyKI also suffer from therapeutic limitations due to adverse effects. we learn the benefits of TyKI over traditional drugs and its key clinical parameters required to start this therapy for maximizing its outcome.
Zitieren
APA
Tasleem, Sultana, N., & Desai, S. (2026). Targeting Cell Signalling Pathways: A Short Review on Tyrosine Kinase Inhibitors. International Journal of Advanced Research in Science Communication and Technology, 17. https://doi.org/10.48175/ijarsct-37803
Vancouver
Tasleem, Sultana N, Desai S. Targeting Cell Signalling Pathways: A Short Review on Tyrosine Kinase Inhibitors. International Journal of Advanced Research in Science Communication and Technology. 2026:17. doi:10.48175/ijarsct-37803
BibTeX
@article{Tasleem2026,
author = {Tasleem and Sultana, Nasreen and Desai, Sushma},
title = {Targeting Cell Signalling Pathways: A Short Review on Tyrosine Kinase Inhibitors},
journal = {International Journal of Advanced Research in Science Communication and Technology},
year = {2026},
pages = {17},
doi = {10.48175/ijarsct-37803}
}
EUVIMED